Stockreport

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Disc Medicine, Inc.  (IRON) 
PDF Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly [Read more]